These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37462997)

  • 1. Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis.
    Li KP; He M; Wan S; Chen SY; Wang CY; Li XR; Yang L
    Int J Surg; 2023 Oct; 109(10):3178-3188. PubMed ID: 37462997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Britton CJ; Andrews JR; Wallis CJD; Sharma V; Leibovich BC; Thompson RH; Boorjian SA; Bhindi B; Costello BA
    Urol Oncol; 2023 Mar; 41(3):125-136. PubMed ID: 38832909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
    de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
    Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis.
    Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q
    Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis.
    Ghatalia P; Handorf EA; Geynisman DM; Deng M; Zibelman MR; Abbosh P; Anari F; Greenberg RE; Viterbo R; Chen D; Smaldone MC; Kutikov A; Uzzo RG
    J Urol; 2022 Jul; 208(1):71-79. PubMed ID: 35212574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
    Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
    Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
    Kato R; Naito S; Numakura K; Hatakeyama S; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N; Obara W
    Int J Clin Oncol; 2022 Mar; 27(3):563-573. PubMed ID: 34973106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications.
    Ditonno F; Bologna E; Licari LC; Franco A; Pettenuzzo G; Leonardo C; Proietti F; Carbonara U; Mir MC; Crivellaro S; Veccia A; Bertolo R; Antonelli A; Autorino R
    World J Urol; 2024 Jul; 42(1):451. PubMed ID: 39066794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes.
    Li KP; Chen SY; Wang CY; Li XR; Yang L
    Front Immunol; 2023; 14():1132466. PubMed ID: 36999026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
    Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
    Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2024; 19(3):e0299102. PubMed ID: 38547226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
    Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
    Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
    Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
    World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
    Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
    Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
    Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
    Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.